Skip to main content

Buckinghamshire

Reply from Meds Management:

Dear Nick,

Further to your letter, I can inform you that Freestyle Libre is currently amber on our Buckinghamshire formulary and can only be initiated by a specialist for new patients. The following five prescriptions will be supplied from primary care.  Patients will then be reviewed at six months in an MDT meeting to discuss the effectiveness of Freestyle Libre.  If there is no improvement in monitoring of the patient’s blood glucose then the use of Freestyle Libre will be discontinued. Prescriptions for patients will follow the NHS England guidance.

All patients must complete a locally approved patient/carer agreement document, have an agreed care plan and attend a diabetes training programme.  They will also need to commit to regular follow ups and monitoring to ensure that we can help them to achieve maximum benefit by using the freestyle Libre and in turn receive great care.

For patients who are self-funding, their case will be discussed in an MDT with a diabetes consultant.  They will be assessed as to whether they met the above criteria before using Freestyle Libre.  Following on recommendation by the specialist,  the patient’s GP can write the following prescriptions.

We were following the RMOC guidance up until April 2019, but we will now be following the NHS England guidance.  Hope we have been able to assist in answering your questions.

Comments

Popular posts from this blog

The CCG Project!

In order to find out the situation around the country for Libre prescribing now that the national policy has been published, I have made the decision to contact many of them to find out their plans.  I have arbitrarily chosen to contact all English CCGs that in December 2018 prescribed Libre via Primary Care to less than 5% of their population (and one specific request from a group member).  I had hoped this would be a small list, but there are 135 CCGs on the list.  I may have bitten off more than I can chew, but I'm committed to doing this and feeding back.  It worked before and hopefully this level of scrutiny will bring similar results. Below is a screenshot of the base document I am sending to each of the CCGs - it has some fields that are merge fields, so don't worry about the brackets and codes in the document (I found a typo, which has now been corrected too) .  The major piece of work with respect to this is finding the right person to contact.  However, I have s

Abbott dX 2022 Barcelona - "Make it Count"

For the past four years I've been invited by Abbott to a conference bringing together people with diabetes from across Europe to discuss various topics.  The first year I was meant to attend, it was my 'man v horse' year (the horse won!), so was unable to attend and then the pandemic hit so two further dX's were held virtually.  I was fortunate to be asked to present at last year's session.  This year's event was back in-person and held in Barcelona, coinciding with the latter part of the ATTD conference.   At this point, I must make it very clear - Abbott invited me to the 2022 European Diabetes Exchange forum (dX), that took place in Barcelona.  I attended this two-day event to connect and interact with inspirational and influential people in the diabetes community.  Abbott paid for my ticket and accommodation. #InvitedbyAbbott.  This is formal and it needs to be - I have not been required to do anything by Abbott as a result of my attendance and I hope that m

July Update - CCGs Under Pressure!

The heat is unbearable in some parts, not only in the environment, but also hopefully the heat directed at the decision-makers in 'non-compliant' CCGs who are either refusing to accept that Libre is a revolutionary tool for many T1s or have agreed to fund, but then set crippling criteria. Latest Prescribing Data Progress in prescribing continues, with stabilisation in Scotland and a continuation of the steady rise in the other three countries of the UK.  The Wales May data should be out this week. As mentioned last month, the situation in Scotland is particularly promising and the excellent Edinburgh Centre for Endocrinology and the Scottish Health Technologies Group have published documents that should significantly help the Libre case.  These documents are based on the first six months of prescribing Libre. Healthcare Improvement Scotland Statement Flash Glucose Monitoring is associated with improved glycaemic control and quality of life in people with type 1 d